Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases

摘要

Background and purpose: Lysophosphatidic acid (LPA) is released from activated platelets.nAcetylsalicylate (aspirin) is the most commonly used antiplatelet drug. The purpose of this studynis to observe whether treatment with acetylsalicylate decreases the LPA level in patients withnischemic cerebrovascular diseases.nMethods: We performed a study examining LPA level in fresh plasma in cases and controlsnenrolled in the LPA and Stroke Prevention Study. Level of LPA was assayed by measuring itsninorganic phosphorus after separation by chromatography.nResults: An elevated LPA level was seen in cases (n5254) with ischemic cerebrovascular diseasen(3.11 ?1.55 mmol/l) compared with 136 healthy controls (1.77 ?1.04 mmol/l) (p,0.001).nAdministration of aspirin (100 mg q.d.) for 1 month significantly lowered LPA level in patientsn(n5142) (2.41 ?1.03 mmol/l) compared with that before taking acetylsalicylate (4.06 n1.03 mmol/l) (p,0.001). However, the LPA level in patients (n536) who stopped acetylsalicylatenafter taking it for 1 month was re-elevated. Before and after taking acetylsalicylate for 1 month,ntheir LPA levels were 4.23 ?1.15 and 1.93 ?0.85 mmol/l, respectively. After 1 monthnwithdrawal, level was 3.90 ?1.09 mmol/l (p,0.001 compared that before taking acetylsalicylate).nConclusion: Our findings support a close association between increased plasma LPA level andnplatelet activation. Acetylsalicylate could decrease plasma LPA levels, which may be used as anmechanism for acetylsalicylate in the prevention of ischemic stroke. [Neurol Res 2008; 30: 366–n369]